Novo Nordisk A/S: pharmaceutical company with a world leading position in diabetes treatment, haemostasis management, growth disorders and hormone replacement therapy

Visit the company website www.novonordisk.com for full information.

Novo Nordisk has the broadest diabetes product portfolio in the industry. We also have a leading position in areas such as haemostasis management, growth disorders and hormone replacement therapy. We will be the world's leading diabetes care company. Our aspiration is to defeat diabetes by finding better methods of diabetes prevention, detection and treatment. Since the early 1920s, Novo Nordisk has been the driving force behind a number of important innovations within the field of insulin research Novo Nordisk has headquarter in Denmark, international production facilities in six countries, affiliates or offices in 68 countries, and a workforce of 18,756 employees (Dec 2003). Approximately 60% of employees are located in Denmark, 40% in the rest of the world - with 19% within R&D. Animal cells are used for manufacturing of NovoSevenÆ (rFVIIa) for treatment of bleeds in haemophilia A and B patients with inhibitors. Further, animal cells are used in R&D for manufacturing of new bioharmaceuticals and production of targets for screening and characterization of new products.

www.novonordisk.com